News

Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related ...
Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...
While Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for ...
U.S. telehealth platform looks to take advantage of Ozempic patent expiring in January, while four manufacturers filed for ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Asking people with type 2 diabetes their language and care preferences is vital to optimise outcomes globally, says Heather Koga As the US writer Ingrid Bengis said, “Words are a form of action, ...
Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announced that human study GLP-1-H25-5 which ...
A recent analysis of adverse drug reactions by Indian Pharmacopoeia Commission revealed that combinations of beta-blockers ...
More than 6,700 University of Nebraska–Lincoln students have been named to the Deans’ List for the spring semester of the ...